

## 35-1729: Polyclonal Antibody to eIF4G (Ab-1232)

<b>Clonality :</b>	Polyclonal
<b>Application :</b>	WB,IHC,IF
<b>Reactivity :</b>	Human
<b>Gene :</b>	EIF4G1
<b>Gene ID :</b>	1981
<b>Uniprot ID :</b>	Q04637
<b>Format :</b>	Purified
<b>Alternative Name :</b>	EIF4G1
<b>Isotype :</b>	Rabbit IgG
<b>Immunogen Information :</b>	Peptide sequence around aa.1230~1234 (P-V-S-P-L) derived from Human eIF4G.

### Description

eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIF4A2, EIF4E and through its N-terminus with PABPC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBP. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis De Gregorio, E. et al. (1998) RNA 4, 828-836. Ohlmann, T. et al. (1996) EMBO J. 15, 1371-1382. Borman, A.M. and Kean, K.M. (1997) Virology 237, 129-136. Gradi, A. et al. (1998) Mol Cell Biol 18, 334-42.

### Product Info

<b>Amount :</b>	50 $\mu$ l / 100 $\mu$ l
<b>Content :</b>	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg <sup>2+</sup> and Ca <sup>2+</sup> ), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
<b>Storage condition :</b>	Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.

### Application Note

Predicted MW: 220kd, Western blotting: 1:500~1:1000, Immunohistochemistry: 1:50~1:100, Immunofluorescence: 1:100~1:200




Figure 1: Western blot analysis of extracts from HepG2 and HT29 cells using eIF4G(Ab-1232) Antibody 35-1729 .




Figure 2: Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using eIF4G(Ab-1232) Antibody 35-1729 (left) or the same antibody preincubated with blocking peptide(right).




Figure 3: Immunofluorescence staining of methanol-fixed HeLa cells using eIF4G(Ab-1232) Antibody 35-1729 .